



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Pre Application

Inventors: Jian Guan, et al.
 Appl. No.: 10/574,280
 Confirm. No.:
 Filed: March 31, 2006
 Title: NEUROPROTECTIVE EFFECTS OF GLY-PRO-
 GLU FOLLOWING INTRAVENOUS INFUSION

Based from:
 PCT International Application Number PCT/US2004/035165
 International Filing Date: October 22, 2004

PATENT APPLICATION

Art Unit: Unassigned
 Examiner: Unassigned

Customer No. 23910

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited in the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 31, 2006.

D. Benjamin Borson (Attorney Signature)
 D. Benjamin Borson, Ph.D., Reg. No. 42,349
 Signature Date: August 31, 2006

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

It is requested that the information identified in this statement be considered by the Examiner and made of record in the above-identified application. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56. If this is a continuation, divisional or continuation-in-part application, it is understood that the Examiner will consider all information which was considered by the Office in a parent application. MPEP §609. Such information therefore is not listed herein unless it is desired that the information be printed on a patent issuing from the subject application.

Enclosed with this statement are the following:

- ☒ Form PTO-1449. The Examiner is requested to initial the form and return it to the undersigned in accordance with M.P.E.P. §609.

3. Copy of International Search Report dated July 11, 2002 for International Application No. PCT/US02/01895 (our ref. no. NRNZ-01016WO0).
4. Copy of International Search Report and Written Opinion dated Feb. 24, 2005 for International Application No. PCT/US04/35165 (our ref. no. NRNZ-01052WO0).
5. Copy of Communication pursuant to Article 96(2) EPC, dated Nov. 24, 2004 for International Application No. 02 753 654.9-2403 (our ref. no. NRNZ-01016EP0).
6. Copy of Communication pursuant to Article 96(2) EPC dated Sept. 21, 2005 for International Application No. 02 753 654.9-2403 (our ref. no. NRNZ-01016EP0).
7. Copy of International Publication No. WO 95/17204 cover sheet.
8. Copy of International Publication No. WO 99/65509 as published.
9. Copy of International Publication No. WO 98/14202 as published.

- ✓ The present application is being/was filed after June 30, 2003. In accordance with the pre-official gazette waiver of 37 CFR 1.98 (a)(2)(i) posted at: pac/dapp/opla/preognotice/idswouscopies.htm, copies of cited U.S. patents and publications are not enclosed. However, copies of cited foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98(a)(2), as still required, except for those items designated by an asterisk (*), which were previously submitted by the applicant in a parent application, from which benefit under 35 U.S.C. §120 is claimed, with an *Information Disclosure Statement* submitted in the parent application which complies with the September 8, 2000 or subsequent revision of 37 C.F.R. §1.98(a-c), as allowed under 37 C.F.R. §1.98(d)(1).

This statement should be considered because:


- ✓ **37 C.F.R. §1.97(b).** This statement qualifies under 37 C.F.R. §1.97, subsection (b) because:
- (1) It is being filed within three months of the filing date of an application other than a continued prosecution application under § 1.53(d);
-- OR --
 - (2) It is being filed within 3 months of entry of a national stage;
-- OR --
 - (3) It is being filed before the mailing date of the first Office Action on the merits,
-- OR --
 - (4) It is being filed before the mailing date of the first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

There is no fee due with this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any deficiencies or credit any overpayment to Deposit Account No. 06-1325.

Respectfully submitted,

FLIESLER MEYER LLP

Date: August 31, 2006

By: 
D. Benjamin Borson, Ph.D.,
Reg. No. 42,349

FLIESLER MEYER LLP
Four Embarcadero Center, Fourth Floor
San Francisco, California 94111-4156
Telephone (415) 362-3800

Receipt date: 09/05/2006

10574280 - GAU: 1654

Sheet 1 of 2



Form PTO-1449 (Substitute)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket Number NRNZ-01052US3		Serial/Patent Number 10/574,280	
Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)				Applicant/Patent Owner Jian Guan, et al.			
				Filing/Issue Date March 31, 2006		Group Art Unit	
U.S. PATENTS							
Examiner Initial		Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date
/MA/		6,187,906 B1	2/13/2001	Guan Jian, et al.	530	331	6/15/99
/MA/		4,444,879	4/24/1984	Foster, et al.	435	7	1/29/81
/MA/		4,816,567	3/28/1989	Cabilly, et al.,	530	387	4/8/83
U.S. PATENT PUBLICATIONS							
Examiner Initial		Patent Application Publication Number	Publication Date	Applicant			
/MA/		US 2002/0151522 A1	10/17/2002	Alexi			
/MA/		US 2002/0027760 A1	2/6/2003	Gluckman, et al.			
PENDING U.S. PATENT APPLICATIONS							
Examiner Initial		Application Number	Filing Date	First Named Inventor	Petition to Expunge? Yes No		
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
/MA/		WO 95/17204 A1	6/29/1995				
/MA/		WO 99/65509 A1	12/23/1999				
/MA/		EP 0366 638 A2	5/2/1990				
/MA/		WO 98/14202 A1	4/9/1998				
OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)							
/MA/		John F. Ballard, et al., "DES(1-3) IGF-I: A Truncated Form of Insulin-Like Growth Factor-I," <u>International Journal of Biochemistry and Cell Biology</u> , Great Britain, Vol. 28, No. 10, 1996, pp. 1085-1087.					

/Maury Audet/

03/30/2009

U.S. Patent Application No. 10/574,280
Attorney Docket No.: NRNZ-01052US3 DBB
dbb/NRNZ/1052US3/101.wpd
Examiner Signature:

- 4 -

Date Considered:

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)		
/MA/		Vicki R. Sara, et al., "Identification of GLY-PRO-GLU (GPE), The Aminoterminal Tripeptide Of Insulin-Like Growth Factor 1 Which Is Truncated In Brain, As A Novel Neuroactive Peptide," <u>Biochemical and Biophysical Research Communications</u> , Vol. 165, No. 2, December 15, 1989, pp.766-771.
		J. Saura, et al., "Neuroprotective Effects Of Gly-Pro-Glu, The N-terminal Tripeptide Of IGF-1, In The Hippocampus In Vitro," <u>NeuroReport</u> , Vol. 10, No. 1, January 18, 1999, pp. 161-164.
		Lena Nilsson-Hakansson, et al., "Effects of IGF-1, Truncated IGF-1 And The Tripeptide Gly-Pro-Glu On Acetylcholine Release From Parietal Cortex Of Rat Brain," <u>NeuroReport</u> , Vol. 4, No. 9, August 6, 1993, (Sept. Issue), pp.1111-1114.
		Harry V. Gelboin, "Cytochrome P450 And Monoclonal Antibodies," <u>Pharmacological Reviews</u> , Vol. 45, No. 4, 1993, pp. 413-453, see entire document.
		Michael J. Brennan, et al., "Chondroitin/Dermatan Sulfate Proteoglycan In Human Fetal Membranes," <u>The Journal Of Biological Chemistry</u> , Vol. 259, No. 22, November 25, 1984, pp. 13742-13750.
		Ikuo Tooyama, et al., "Production and Immunohistochemical Application Of Antiserum Against Tyr-D-Ala-Phe, A N-Terminal Tripeptide Common To Dermorphine/Deltorphin Family," <u>Elsevier Science Inc.</u> , Peptides, 21, 2000, pp. 1649-1655.
/MA/		Jose Luis Millan, et al., "Seminoma-Derived Nagao Isozyme Is Encoded By A Germ-Cell Alkaline Phosphatase Gene," <u>Proc. National Academy Science USA</u> , Developmental Biology, Vol. 85, May 1988, pp. 3024-3028.
Examiner /Maury Audet/		Date Considered 03/30/2009
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		
<p>*1 = Copy not submitted because it was submitted in prior application SN <u> </u> / <u> </u>, filed <u> </u>, 20<u> </u>, relied on under 35 USC §120.</p>		
<p>*2 = Copy not submitted because it was submitted in prior application SN <u> </u> / <u> </u>, filed <u> </u>, 20<u> </u>, relied on under 35 USC §120.</p>		